Merck’s Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?
Merck’s Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?
Merck’s Keytruda: A Deep Dive
Merck’s Keytruda: A Deep Dive
10 Takeover Targets to Watch This Fall
10 Takeover Targets to Watch This Fall
Θετικές εξελίξεις στην πολλαπλή σκλήρυνση
Θετικές εξελίξεις στην πολλαπλή σκλήρυνση
Roche’s Tecentriq scores solo win in lung cancer. But can it challenge Merck’s Keytruda?
Roche’s Tecentriq scores solo win in lung cancer. But can it challenge Merck’s Keytruda?
Roche’s Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals
Roche’s Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals
Keytruda Approvals: A Timeline
Keytruda Approvals: A Timeline
Πώς θα κινηθεί η αγορά γονιδιακής επεξεργασίας
Πώς θα κινηθεί η αγορά γονιδιακής επεξεργασίας
AstraZeneca’s Imfinzi tees up small cell lung cancer fight with Roche
AstraZeneca’s Imfinzi tees up small cell lung cancer fight with Roche
FDA Action Alert: Merck, Agios and AMAG Pharma
FDA Action Alert: Merck, Agios and AMAG Pharma
Απεβίωσε ο Γιάννης Βλόντζος
Απεβίωσε ο Γιάννης Βλόντζος
Καινοτόμος θεραπεία για την πολλαπλή σκλήρυνση
Καινοτόμος θεραπεία για την πολλαπλή σκλήρυνση
Asco 2019 event analyser – low-key meeting belies some huge stock moves
Asco 2019 event analyser – low-key meeting belies some huge stock moves
Move aside, Humira. Merck’s Keytruda will capture industry’s top sales spot in 2024: report
Move aside, Humira. Merck’s Keytruda will capture industry’s top sales spot in 2024: report
All the ASCO skinny: Lynparza’s pancreatic win, Amgen’s KRAS spotlight, Merck’s history-busting and more
All the ASCO skinny: Lynparza’s pancreatic win, Amgen’s KRAS spotlight, Merck’s history-busting and more
AstraZeneca, Merck make case for PARP’s place in pancreatic cancer
AstraZeneca, Merck make case for PARP’s place in pancreatic cancer
